Page last updated: 2024-09-03

imatinib mesylate and Skin Diseases

imatinib mesylate has been researched along with Skin Diseases in 30 studies

Research

Studies (30)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (56.67)	29.6817
2010's	10 (33.33)	24.3611
2020's	3 (10.00)	2.80

Authors

Authors	Studies
Egusa, C; Harada, K; Hayakawa, K; Maeda, T; Okubo, Y	1
Huang, W; Li, J; Li, X; Qiu, F; Wu, X; Yao, G; Zhang, J; Zhu, S	1
Saroha, M	1
Baird, K; Booher, S; Comis, LE; Cowen, EW; Figg, WD; Flanders, KC; Hakim, FT; Joe, GO; Mitchell, SA; Pavletic, SZ; Rose, JJ; Sarantopoulos, S; Steinberg, SM; Takebe, N; Yao, L	1
Arai, S; Chai, X; Chen, GL; Flowers, ME; Green, M; Hyun, TS; Inamoto, Y; Jagasia, MH; Jaglowski, S; Khera, N; Lee, SJ; Martin, PJ; Mayer, SA; Miklos, DB; Palmer, J; Pidala, J; Pusic, I; Sarantopoulos, S; Shulman, HM; Storer, BE; Wood, WA	1
Desar, IM; Kaal, SE; van de Kerkhof, PC; van der Graaf, WT; van Erp, NP; van Herpen, CM	1
Turhan, AG	1
Dickinson, TM; Jones, CM; Salvado, A	1
Akhmetshina, A; Busch, N; Dees, C; Distler, JH; Distler, O; Schett, G; Venalis, P; Zwerina, J	1
Cowen, EW	1
Bacigalupo, A; Balduzzi, A; Cimminiello, M; Gabrielli, A; Gini, G; Leoni, P; Locatelli, F; Mordini, N; Olivieri, A; Raimondi, R; Sanna, A; Zecca, M	1
Goerdt, S; Krömer-Olbrisch, T; Kurzen, H; Mohme, H; Stadler, R; Wagner, C	1
Kabashima, K; Miyachi, Y; Murata, T	1
Dalle, S; Shear, NH; Thomas, L	1
Martin, L	1
Arnan, M; Duarte, RF; Manresa, F; Ortí, G; Peralta, T; Sánchez-Ortega, I; Servitje, O	1
Horne, HL; Maung, Z; Reddy, H	1
Burge, S; Peniket, A; Rodgers, CJ; Scarisbrick, J	1
Ault, P; Cortes, J; Ferrajoli, A; Kaled, ES; Kantarjian, H; Koller, C; Letvak, L; Rios, MB; Thomas, D; Wierda, W	1
Belinchon-Romero, I; Fernandez-Abellan, P; Pascual-Ramirez, JC; Rivas, C; Sanchez-Gonzalez, B; Vegara-Aguilera, G	1
Dippel, E; Hildenbrand, R; Hochhaus, A; Schadendorf, D; Ugurel, S	1
Creamer, D; du Vivier, AW; Milojkovic, D; Mufti, GJ; Salisbury, JR; Short, K	1
Armand, JP; Boige, V; Escudier, B; Le Cesne, A; Le Chevalier, T; Lhomme, C; Malka, D; Pautier, P; Robert, C; Soria, JC; Spatz, A; Wechsler, J	1
Scheinfeld, N; Schienfeld, N	1
Grzybowski, G; Mikołajczyk, K; Samborski, W; Walkowiak, B; Zaba, R	1
Berneburg, M; Bitzer, M; Metzler, G; Müller-Hermelink, HK; Röcken, M; Weyrauch, S; Yazdi, AS	1
Bhatia, K; Doval, DC; Talwar, V	1
Kano, Y	1
Burgin, S; Heidary, N; Naik, H	1
Contentin, N; Courville, P; Duval-Modeste, AB; Goldman, J; Joly, P; Lambert, A; Musette, P	1

Reviews

7 review(s) available for imatinib mesylate and Skin Diseases

Article	Year
How pharmacogenomics of biological response modifiers will influence clinical response and toxicity in dermatology. International journal of dermatology, 2011, Volume: 50, Issue:1 Topics: Antibodies, Monoclonal, Murine-Derived; Benzamides; Dermatologic Agents; Drug Resistance; ErbB Receptors; Humans; Imatinib Mesylate; Immunologic Factors; Pharmacogenetics; Piperazines; Polymorphism, Genetic; Precision Medicine; Pyrimidines; Receptors, IgG; Rituximab; Skin Diseases; Tumor Necrosis Factor-alpha	2011
[What's new in dermatological treatments?]. Annales de dermatologie et de venereologie, 2010, Volume: 137 Suppl 4 Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cyclosporine; Dermatofibrosarcoma; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Follow-Up Studies; Gels; HIV Infections; Humans; Imatinib Mesylate; Immunoglobulin G; Immunosuppressive Agents; Ipilimumab; Melanoma; Neoplasm Staging; Organophosphonates; Piperazines; Psoriasis; Pyrimidines; Receptors, Tumor Necrosis Factor; Skin Diseases; Skin Neoplasms; Survival Analysis; Tenofovir; Treatment Outcome; Ustekinumab	2010
More than skin deep? Emerging therapies for chronic cutaneous GVHD. Bone marrow transplantation, 2013, Volume: 48, Issue:3 Topics: Antibodies, Monoclonal, Murine-Derived; Benzamides; Chronic Disease; Graft vs Host Disease; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Rituximab; Skin Diseases; Ultraviolet Therapy	2013
Cutaneous side-effects of kinase inhibitors and blocking antibodies. The Lancet. Oncology, 2005, Volume: 6, Issue:7 Topics: Antibodies, Blocking; Antineoplastic Agents; Benzamides; Benzenesulfonates; ErbB Receptors; Hair Diseases; Humans; Imatinib Mesylate; Nail Diseases; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Skin Diseases; Sorafenib	2005
A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. Journal of drugs in dermatology : JDD, 2006, Volume: 5, Issue:2 Topics: Animals; Benzamides; Dermatofibrosarcoma; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Diseases; Skin Neoplasms	2006
[Adverse drug reactions induced by molecular target therapy]. Arerugi = [Allergy], 2007, Volume: 56, Issue:12 Topics: Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Cetuximab; Communicable Diseases; ErbB Receptors; Etanercept; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Immunoglobulin G; Infliximab; Lung Diseases; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Tumor Necrosis Factor; Skin Diseases; Tumor Necrosis Factor-alpha	2007
Chemotherapeutic agents and the skin: An update. Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids	2008

Trials

6 trial(s) available for imatinib mesylate and Skin Diseases

Article	Year
Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents; Child; Drug Administration Schedule; Fasciitis; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Joints; Leukemia; Male; Middle Aged; Mycophenolic Acid; Pilot Projects; Prednisone; Range of Motion, Articular; Recurrence; Skin Diseases; Tacrolimus; Transplantation, Homologous	2015
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Jan-15, Volume: 22, Issue:2 Topics: Adult; Aged; B-Lymphocytes; Cross-Over Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Prospective Studies; Rituximab; Sclerosis; Skin Diseases; Tumor Necrosis Factor Receptor Superfamily, Member 7; Young Adult	2016
Phase II open label trial of imatinib in polycythemia rubra vera. International journal of hematology, 2008, Volume: 88, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Hematocrit; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Platelet Count; Polycythemia Vera; Pyrimidines; Remission Induction; Skin Diseases	2008
Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood, 2009, Jul-16, Volume: 114, Issue:3 Topics: Adolescent; Adult; Benzamides; Child; Female; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Intestinal Diseases; Lung Diseases; Male; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy; Skin Diseases; Survival Analysis; Treatment Outcome	2009
Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:2 Topics: Adult; Benzamides; Bone Marrow Transplantation; Chronic Disease; Dasatinib; Drug Resistance; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Sclerosis; Skin Diseases; Thiazoles; Transplantation, Homologous	2012
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood, 2003, Jun-15, Volume: 101, Issue:12 Topics: Adult; Aged; Benzamides; Bone Marrow; Cardiovascular Diseases; Enzyme Inhibitors; Eosinophils; Female; Fusion Proteins, bcr-abl; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Middle Aged; Nervous System Diseases; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Skin Diseases	2003

Other Studies

17 other study(ies) available for imatinib mesylate and Skin Diseases

Article	Year
Topical application of imatinib mesylate ameliorated psoriasis-like skin lesions in imiquimod-induced murine model via angiogenesis inhibition. Experimental dermatology, 2023, Volume: 32, Issue:6 Topics: Animals; Disease Models, Animal; Humans; Imatinib Mesylate; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Diseases; Vascular Endothelial Growth Factor A	2023
Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report. Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:4 Topics: Aged; Drug Eruptions; Drug Monitoring; Eczema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Skin Diseases	2020
Cutaneous adverse reaction to imatinib in a case of childhood chronic myeloid leukemia. Pediatric blood & cancer, 2020, Volume: 67, Issue:12 Topics: Antineoplastic Agents; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prognosis; Skin Diseases	2020
A successful approach to overcome imatinib-induced skin toxicity in a GIST patient. Anti-cancer drugs, 2016, Volume: 27, Issue:6 Topics: Aged; Antineoplastic Agents; Clemastine; Doxycycline; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Skin Diseases	2016
Reversible skin telangiectasia induced by imatinib mesylate in chronic myeloid leukemia. Leukemia & lymphoma, 2016, Volume: 57, Issue:11 Topics: Adult; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Remission, Spontaneous; Skin Diseases; Telangiectasis; Withholding Treatment	2016
Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis and rheumatism, 2009, Volume: 60, Issue:1 Topics: Animals; Antibiotics, Antineoplastic; Benzamides; Bleomycin; Disease Models, Animal; Fibrillins; Fibrosis; Imatinib Mesylate; Mice; Mice, Inbred DBA; Mice, Mutant Strains; Microfilament Proteins; Phenotype; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Scleroderma, Systemic; Skin; Skin Diseases	2009
A call for more dermatologic input into chronic graft-vs-host disease clinical trials. Archives of dermatology, 2009, Volume: 145, Issue:3 Topics: Benzamides; Chronic Disease; Clinical Trials as Topic; Dermatology; Graft vs Host Disease; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Localized; Skin Diseases	2009
Langerhans cell histiocytosis: treatment failure with imatinib. Archives of dermatology, 2009, Volume: 145, Issue:8 Topics: Adult; Aged, 80 and over; Benzamides; Histiocytosis, Langerhans-Cell; Humans; Imatinib Mesylate; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Diseases; Treatment Failure; Young Adult	2009
Prompt lightening of acral lentiginosis in a GIST patient after treatment with imatinib mesylate. Journal of the European Academy of Dermatology and Venereology : JEADV, 2010, Volume: 24, Issue:12 Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Skin Diseases	2010
Skin fragility and blistering secondary to imatinib. Clinical and experimental dermatology, 2012, Volume: 37, Issue:5 Topics: Antineoplastic Agents; Benzamides; Blister; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Skin Diseases	2012
Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. Blood, 2003, Mar-15, Volume: 101, Issue:6 Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Skin Diseases	2003
Dose-dependent severe cutaneous reactions to imatinib. British journal of cancer, 2003, Apr-22, Volume: 88, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Hypersensitivity; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Skin Diseases	2003
Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia. Leukemia, 2003, Volume: 17, Issue:7 Topics: Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Female; Histocytochemistry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Skin Diseases	2003
[The hypereosinophilic syndrome: case report]. Annales Academiae Medicae Stetinensis, 2006, Volume: 52 Suppl 2 Topics: Adult; Benzamides; Bone Marrow; Diagnosis, Differential; Eosinophils; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferons; Lymphatic Diseases; Male; Methylprednisolone; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Diseases; Treatment Outcome	2006
Lymphomatoid granulomatosis induced by imatinib-treatment. Archives of dermatology, 2007, Volume: 143, Issue:9 Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Diseases; Lymphomatoid Granulomatosis; Piperazines; Pyrimidines; Skin Diseases	2007
Imatinib mesylate induced skin hypopigmentation. The Journal of the Association of Physicians of India, 2007, Volume: 55 Topics: Antineoplastic Agents; Benzamides; Genes, abl; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin Diseases	2007
[Imatinib-induced DRESS]. Annales de dermatologie et de venereologie, 2008, Volume: 135, Issue:5 Topics: Aged; Antineoplastic Agents; Benzamides; Drug Hypersensitivity; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin; Skin Diseases	2008